Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00678899 · ClinicalTrials.gov registry record · NA

Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System

A NA study of Sensorineural Hearing Loss, sponsored by Cochlear.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT00678899 is a NA study of Sensorineural Hearing Loss that has completed, run by Cochlear. The registered enrollment target is 50 participants, below the 127-participant average among 13 other Sensorineural Hearing Loss trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00678899, a NA study of Sensorineural Hearing Loss, has completed, sponsored by Cochlear.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the safety and efficacy associated with the provision of acoustic and electric sound processing to individuals who demonstrate significant residual low-frequency hearing and profound high-frequency (above 1500 Hz) sensorineural hearing loss. Delivery of acoustic-electric stimulation will be provided by the Nucleus Hybrid L24 cochlear implant system.

Conditions Studied

Interventions

  • DEVICE Nucleus Hybrid L24

Study Locations (1)

New York

  • NYU Medical Center - New York

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2008-04
Est. Completion 2014-07
Phase NA

Sponsor

Cochlear

34 total trials

What the Registry Record Tells You About NCT00678899

The ClinicalTrials.gov registry entry for NCT00678899 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 127-participant average among 13 other Sensorineural Hearing Loss trials with a reported enrollment target (61% lower). The listed sponsor is Cochlear, which has 34 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sensorineural Hearing Loss appearing as the primary indexed condition, and to 1 intervention - of which Nucleus Hybrid L24 is the first listed.

NCT00678899 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00678899 about?

NCT00678899 is a clinical study titled "Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System". The purpose of this study is to evaluate the safety and efficacy associated with the provision of acoustic and electric sound processing to individuals who demonstrate significant residual low-frequency hearing and profound high-frequency (above 1500 Hz) sensorineural hearing loss. Delivery of acous...

What is the current status of trial NCT00678899?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2008-04. Estimated completion is 2014-07.

What conditions does trial NCT00678899 study?

This clinical trial studies the following conditions: Sensorineural Hearing Loss.

What interventions are being tested in trial NCT00678899?

The interventions under investigation include: Nucleus Hybrid L24 (DEVICE).

Who is sponsoring clinical trial NCT00678899?

This trial is sponsored by Cochlear, which has 34 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00678899 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sensorineural Hearing Loss

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.